Marinus Pharmaceuticals (NASDAQ:MRNS) received a $19.00 price objective from stock analysts at Cantor Fitzgerald in a report released on Tuesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price indicates a potential upside of 102.13% from the stock’s previous close.

MRNS has been the subject of a number of other reports. BidaskClub lowered Marinus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, June 22nd. LADENBURG THALM/SH SH started coverage on Marinus Pharmaceuticals in a report on Wednesday, June 6th. They set a “buy” rating and a $20.00 price objective for the company. ValuEngine raised Marinus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, June 2nd. Finally, Mizuho reissued a “buy” rating and set a $13.00 price objective on shares of Marinus Pharmaceuticals in a report on Thursday, August 2nd. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $19.67.

Shares of Marinus Pharmaceuticals stock opened at $9.40 on Tuesday. Marinus Pharmaceuticals has a one year low of $3.31 and a one year high of $9.87.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.09). analysts anticipate that Marinus Pharmaceuticals will post -0.73 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Trexquant Investment LP bought a new stake in Marinus Pharmaceuticals during the 2nd quarter worth approximately $102,000. GSA Capital Partners LLP bought a new stake in Marinus Pharmaceuticals during the 2nd quarter worth approximately $141,000. Jennison Associates LLC increased its holdings in Marinus Pharmaceuticals by 0.8% during the 2nd quarter. Jennison Associates LLC now owns 2,757,356 shares of the biopharmaceutical company’s stock worth $19,495,000 after purchasing an additional 21,733 shares in the last quarter. Rhumbline Advisers bought a new stake in Marinus Pharmaceuticals during the 2nd quarter worth approximately $245,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in Marinus Pharmaceuticals during the 2nd quarter worth approximately $363,000. 63.64% of the stock is owned by hedge funds and other institutional investors.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid.

See Also: Trading Strategy Methods for Individual Investors

Analyst Recommendations for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.